Skip to main content

Contraceptive

0
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Bayer
BayerLEVERKUSEN, Germany
1 program
Norethisterone enantate/estradiol valerateN/A1 trial
Active Trials
NCT03901131Completed296Est. Feb 2022
Essential Pharmaceuticals
1 program
Test ProductN/A1 trial
Active Trials
NCT05370196Completed600Est. May 2023

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Essential PharmaceuticalsTest Product
BayerNorethisterone enantate/estradiol valerate

Clinical Trials (2)

Total enrollment: 896 patients across 2 trials

Synthetic Male Condom Slippage-Breakage Study

Start: Jun 2022Est. completion: May 2023600 patients
N/ACompleted
NCT03901131BayerNorethisterone enantate/estradiol valerate

PROMES: A Clinical Study in Which Researchers Want to Learn More About the Safety Profile of MESIGYNA (Norethisterone Enantate 50 mg and Estradiol Valerate 5 mg) Used as a Medication to Prevent Pregnancy for Adult Women in Reproductive Age in the Peruvian Population at the Outpatient Clinic.

Start: Aug 2019Est. completion: Feb 2022296 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.